Title: Sinomenine hydrochloride improves DSS-induced colitis in mice through inhibition of
the Notch signaling pathway
Version: 3 Date: 26 Sep 2024
Reviewer's report:
This article is a study on the therapeutic effect of Sinomenine hydrochloride (SH) on ulcerative
colitis (UC) in mice. The article provides detailed information on experimental design, methods,
results, and discussion. Here are some potential issues and shortcomings:
1. Sample Size: The study used 24 mice, with six in each group. While this is a common sample
size for preliminary studies, a smaller sample may affect the statistical power and extrapolation
of the results.
2. Randomization and Blinding: The article does not clearly state whether randomization and
blinding were used in the experiment. These measures help reduce experimental bias and
subjectivity.
3. Dose Selection: The study used two dose levels of SH (20 mg/kg and 60 mg/kg) but did not
provide a detailed basis for dose selection. Ideally, doses should be chosen based on previous
literature or dose-response studies. Exploring a wider range of dosages could provide a more
comprehensive understanding of the dose-response relationship and optimal therapeutic dose.
4. Long-term Effects and Safety: The study only observed short-term therapeutic effects and did
not assess the potential side effects and safety of long-term use of SH.
5. Mechanism Exploration: Although the article suggests that SH may treat UC by inhibiting
the Notch signaling pathway, the exploration of the mechanism may not be in-depth enough.
Further investigation is needed to elucidate the detailed molecular mechanisms.
6. Clinical Relevance: The study was conducted in an animal model, and whether its results can
be directly translated to human patients requires further clinical research for verification.
7. Interpretation of Results: The results in the article need to be interpreted cautiously. For
example, although SH reduced the levels of inflammatory factors, the article did not directly
prove that this was achieved through the Notch signaling pathway.
8. Lack of Comparison with Standard Treatments: The study does not compare SH with existing
standard treatments for UC. Such comparisons would be valuable to position SH in the context
of current therapeutic options.
If the above issues can be adjusted, please make the modifications directly in the manuscript. If
they are difficult to adjust, it is recommended to explain in the Limitations section.
Title: Sinomenine hydrochloride improves DSS-induced colitis in mice through inhibition of
the Notch signaling pathway
Version: 3 Date: 26 Sep 2024
Reviewer's report:
This article is a study on the therapeutic effect of Sinomenine hydrochloride (SH) on ulcerative
colitis (UC) in mice. The article provides detailed information on experimental design, methods,
results, and discussion. Here are some potential issues and shortcomings:
1. Sample Size: The study used 24 mice, with six in each group. While this is a common sample
size for preliminary studies, a smaller sample may affect the statistical power and extrapolation
of the results.
2. Randomization and Blinding: The article does not clearly state whether randomization and
blinding were used in the experiment. These measures help reduce experimental bias and
subjectivity.
3. Dose Selection: The study used two dose levels of SH (20 mg/kg and 60 mg/kg) but did not
provide a detailed basis for dose selection. Ideally, doses should be chosen based on previous
literature or dose-response studies. Exploring a wider range of dosages could provide a more
comprehensive understanding of the dose-response relationship and optimal therapeutic dose.
4. Long-term Effects and Safety: The study only observed short-term therapeutic effects and did
not assess the potential side effects and safety of long-term use of SH.
5. Mechanism Exploration: Although the article suggests that SH may treat UC by inhibiting
the Notch signaling pathway, the exploration of the mechanism may not be in-depth enough.
Further investigation is needed to elucidate the detailed molecular mechanisms.
6. Clinical Relevance: The study was conducted in an animal model, and whether its results can
be directly translated to human patients requires further clinical research for verification.
7. Interpretation of Results: The results in the article need to be interpreted cautiously. For
example, although SH reduced the levels of inflammatory factors, the article did not directly
prove that this was achieved through the Notch signaling pathway.
8. Lack of Comparison with Standard Treatments: The study does not compare SH with existing
standard treatments for UC. Such comparisons would be valuable to position SH in the context
of current therapeutic options.
If the above issues can be adjusted, please make the modifications directly in the manuscript. If
they are difficult to adjust, it is recommended to explain in the Limitations section.
Please review this paper.
user
Title: Sinomenine hydrochloride improves DSS-induced colitis in mice through inhibition of
the Notch signaling pathway
Version: 3 Date: 26 Sep 2024
Reviewer's report:
This article is a study on the therapeutic effect of Sinomenine hydrochloride (SH) on ulcerative
colitis (UC) in mice. The article provides detailed information on experimental design, methods,
results, and discussion. Here are some potential issues and shortcomings:
1. Sample Size: The study used 24 mice, with six in each group. While this is a common sample
size for preliminary studies, a smaller sample may affect the statistical power and extrapolation
of the results.
2. Randomization and Blinding: The article does not clearly state whether randomization and
blinding were used in the experiment. These measures help reduce experimental bias and
subjectivity.
3. Dose Selection: The study used two dose levels of SH (20 mg/kg and 60 mg/kg) but did not
provide a detailed basis for dose selection. Ideally, doses should be chosen based on previous
literature or dose-response studies. Exploring a wider range of dosages could provide a more
comprehensive understanding of the dose-response relationship and optimal therapeutic dose.
4. Long-term Effects and Safety: The study only observed short-term therapeutic effects and did
not assess the potential side effects and safety of long-term use of SH.
5. Mechanism Exploration: Although the article suggests that SH may treat UC by inhibiting
the Notch signaling pathway, the exploration of the mechanism may not be in-depth enough.
Further investigation is needed to elucidate the detailed molecular mechanisms.
6. Clinical Relevance: The study was conducted in an animal model, and whether its results can
be directly translated to human patients requires further clinical research for verification.
7. Interpretation of Results: The results in the article need to be interpreted cautiously. For
example, although SH reduced the levels of inflammatory factors, the article did not directly
prove that this was achieved through the Notch signaling pathway.
8. Lack of Comparison with Standard Treatments: The study does not compare SH with existing
standard treatments for UC. Such comparisons would be valuable to position SH in the context
of current therapeutic options.
If the above issues can be adjusted, please make the modifications directly in the manuscript. If
they are difficult to adjust, it is recommended to explain in the Limitations section.
assistant